Infection Control Applications definition

Infection Control Applications shall have the same meaning as that term is defined in the License Agreement.
Sample 1Sample 2Sample 3
Infection Control Applications which shall mean the testing of (i) any human biological materials or samples; or (ii) air or physical surfaces; in each case solely for the purpose of detecting, measuring, identifying, and/or determining viability of microbial agents in order to reduce the spread of infections in patients or otherwise healthy individuals, including but not limited to healthcare associated infections (HAIs) within healthcare facilities; provided, however, that Infection Control Applications shall not include any uses other than as expressly set forth above in this clause (f), and, without limiting the foregoing, shall not include: (1) Bioterrorism Applications; and (2) the Excluded Applications; and provided further that the license, sublicense and rights granted under Section 2.1 with respect to Infection Control Applications shall be limited to CUDA with respect to commercial activities but not with respect to development activities (for which Company may use other instruments), and shall not include any other instruments, except as expressly contemplated under Section 2.5; and
Sample 1Sample 2Sample 3

Examples of Infection Control Applications in a sentence

  • Company agrees to comply directly with the obligations set forth in the PHRI Agreement that arise as a result of the activities of Company and its Affiliates under this Agreement with respect to Infection Control Applications (including timely paying to Gen-Probe the royalties payable to PHRI or its successors or assigns under the PHRI Agreement in accordance with Section 3.1(b) of this Agreement).

  • If such officers are unable to resolve such issue within 30 days of commencing such negotiations, then the matter shall be submitted to an individual with expertise in the development of NATs for Infection Control Applications who is acceptable to both of the parties (the “Expert”), or if the parties are unable to agree upon the Expert, each party shall select its own individual who would qualify as an Expert and those two individuals shall select the Expert.

  • Gen-Probe reserves and retains all rights to the Gen-Probe Patents and Gen-Probe Know-How for all uses outside the Company Field, all rights to the Stanford Patents granted under the Stanford Agreement for all uses outside the Company Field, and all rights granted under the PHRI Agreement for all uses outside Infection Control Applications.

  • Gen-Probe and Company wish to amend the License Agreement to, among other things, clarify the nature of the Company’s rights with respect to Infection Control Applications (as such term is defined in the License Agreement).

  • For the avoidance of doubt, Company acknowledges that, with respect to Infection Control Applications, Gen-Probe shall have no obligation to provide Information about any organism other than MRSA, VREF and C.diff (including combinations thereof and, solely with respect to MRSA, in combination with Methicillin-sensitive Staphylococcus aureus) unless otherwise agreed to in writing by Gen-Probe.

  • Company may propose to Gen-Probe the joint development of NATs for commercialization by Gen-Probe on Panther and other instruments for one or more Infection Control Applications other than MRSA, VREF and C.diff.

  • The royalties payable by Company as provided under Sections 3.1(a) and (b) shall not exceed a maximum of [*] of aggregate annual Net Sales, except that such maximum shall instead be [*] of aggregate annual Net Sales of Products for Infection Control Applications.

  • The royalties payable by Company as provided under Sections 3.1(a) and (b) shall not exceed a maximum of 14.5% of aggregate annual Net Sales, except that such maximum shall instead be 16.0% of aggregate annual Net Sales of Products for Infection Control Applications.

  • Company may propose to Gen-Probe the joint development of NATs for commercialization by Gen-Probe on Panther and other instruments for one or more Infection Control Applications other than [*].

  • For the avoidance of doubt, Company acknowledges that, with respect to Infection Control Applications, Gen-Probe shall have no obligation to provide Information about any organism other than [*] unless otherwise agreed to in writing by Gen-Probe.

Related to Infection Control Applications

  • Biologics License Application or “BLA” means, with respect to a country or extra-national territory, a request for permission to introduce, distribute, sell or market a biologic product in such country or some or all of such extra-national territory, including pursuant to 21 CFR 601.2 in the U.S.

  • Practical application means to manufacture in the case of a composition or product, to practice in the case of a process or method, or to operate in the case of a machine or system; and, in each case, under such conditions as to establish that the invention is being utilized and that its benefits are, to the extent permitted by law or government regulations, available to the public on reasonable terms.

  • Approval Application means a BLA, NDA or similar application or submission for a Product filed with a Regulatory Authority in a country or group of countries to obtain marketing approval for a biological or pharmaceutical product in that country or group of countries.

  • Marketing Authorization Application or “MAA” means an application for Regulatory Approval (but excluding Pricing Approval) in any particular jurisdiction other than the U.S.

  • Mobile Application means a specialized software program downloaded onto a wireless communication device.

  • Infection means the entry and development or multiplication of an infectious agent in the body of humans and animals that may constitute a public health risk;

  • Initial application means the Application first provided to MFA on or before an Application Deadline to request an allocation of Tax Credits.

  • Account Application or “Application” shall mean the application, as may be amended from time to time, by which this Agreement is established between the Depositor (or following the death of the Depositor, the Beneficiary) and the Custodian. The statements contained therein shall be incorporated into this Agreement.

  • Regulatory Approval Application means any application submitted to an appropriate Regulatory Authority seeking any Regulatory Approval.

  • Drug Approval Application means an application for Regulatory Approval required before commercial sale or use of a Licensed Product as a drug in a regulatory jurisdiction.